Download PDF

ES Journal of Cardiology

DOI: 10.59152/ESJC/1023

ISSN: 2768-0533

Evaluating the Interactions between Endothelial and Smooth Muscle Cells in the Presence of Drug-Eluting Stents and Platelets: Is Interleukin6 a New Possible Therapeutic Target for In-Stent Restenosis?

  • Research Article

  • Clarissa Campo Dall’Orto*, Daniel da Conceição Rabelo, Rosely Cabette Barbosa Alves, and Durvanei Augusto Maria
  • Department of Molecular Biology-Butantan Institute, Faculty of Medicine of University of São Paulo, São Paulo, São Paulo, Brazil
  • *Corresponding author: Clarissa Campo Dall’Orto, Department of Molecular Biology-Butantan Institute Av. Vital Brasil, 1500 - Butantã, São Paulo - SP, 05503-900, Brazil
  • Received: Nov 04, 2021, Accepted: Nov 23, 2021; Published: Nov 25, 2021


The success of percutaneous coronary intervention (PCI) procedures is limited by in-stent restenosis (ISR). The use of drug-eluting stents (DES) decreased the incidence of ISR; however, ISR continues to affect a percentage of patients with ischemic cardiac events. Therefore, there is room for improvement considering not only the effectiveness of DES but also the adjunct pharmacological interventions for patients after PCI. Interleukin 6 (IL-6) can stimulate the growth of vascular smooth muscle cells (SMCs) in a platelet-derived growth factor (PDGF)-dependent manner and that antibodies against the IL-6 receptor reduced intimal hyperplasia in mice. In this study, our aim is to develop an in vitro study, based on co-cultures of endothelial cells (EC) and SMCs in the presence of platelets and stents, to analyze the cytokine responses (IL-6 and other inflammation markers) associated with ISR, in the quest for new therapeutic targets. Overall, in the presence of platelet-rich plasma (PRP), there was an increase in the production of reactive oxygen species in the groups that received the stents, probably because platelets potentiate stent-associated oxidative stress. Moreover, the analysis of the expression of inflammatory markers showed a difference in the expression of IL-6 only in the groups that received stents, which further increased in the presence of platelets. Altogether, our findings suggest that the down regulation of IL-6 expression using pharmacologic inhibitors is a possible new therapeutic strategy in the context of ISR.


Percutaneous coronary intervention; In-stent restenosis; Interleukin 6